UK Markets close in 5 hrs 14 mins

Novartis AG (0QLR.IL)

IOB - IOB Delayed price. Currency in CHF
Add to watchlist
79.12-0.85 (-1.06%)
As of 10:38AM GMT. Market open.
Full screen
Loading interactive chart…
  • Globe Newswire

    Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA

    Submission supported by comprehensive analytical and clinical data package Denosumab indicated for treating variety of conditions including osteoporosis in postmenopausal women1,2 Sandoz continues to build biosimilars portfolio to increase patient access to high-quality therapies and support healthcare system sustainability Basel, February 06, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the US Food and Drug Administration (FDA) has accept

  • Globe Newswire

    Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®

    In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the HS Clinical Response (HiSCR) measure1 Safety findings were consistent with the well-established safety profile of Cosentyx in its approved indications1 HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like a

  • Simply Wall St.

    Novartis Full Year 2022 Earnings: Misses Expectations

    Novartis ( VTX:NOVN ) Full Year 2022 Results Key Financial Results Revenue: US$51.8b (down 2.0% from FY 2021). Net...